Voting Rights
28 Febrero 2007 - 8:51AM
UK Regulatory
RNS Number:0481S
Ardana PLC
28 February 2007
Ardana plc (LSE: ARA) - voting rights and capital
Edinburgh, UK, 28 February 2007; In conformity with the Transparency Directive's
transitional provision 6 we would like to notify the market of the following:
As at 28 February 2007, the issued share capital and voting rights of Ardana plc
are as follows:
Ardana plc's capital consists of 65,511,729 ordinary 1p shares with voting
rights attached of one vote per ordinary share of which 12,681 ordinary shares
are held in Treasury.
Therefore, the total number of voting rights in Ardana plc is 65,499,048.
The above figure (65,499,048) may be used by shareholders as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, Ardana plc under the FSA's
Disclosure and Transparency Rules.
Enquiries
For more information contact:
Maureen Lindsay + 44 (0) 131 226 8550
Ardana
Julia Phillips/John Gilbert +44 (0)20 7831 3113
Financial Dynamics
(corporate and financial media relations)
About Ardana
Ardana plc is a pharmaceutical company focused on the discovery, development and
marketing of innovative products to improve human reproductive health, a $25.5
billion market*.
Since its foundation, Ardana has maintained a broad and balanced portfolio to
manage risk and actively pursues product and technology in-licensing and
out-licensing to maintain a robust pipeline.
Ardana's four lead products are summarised below:
* Emselex(R), a once a day treatment for the symptoms of overactive bladder
which Ardana has exclusive UK marketing and promotion rights and is being
distributed in collaboration with Novartis Pharmaceuticals UK Limited;
* StriantTM SR, a testosterone replacement therapy that has been launched by
Ardana through its own sales force in the UK and through marketing partners
in certain European countries, as a treatment for men with confirmed
hypogonadism;
* Invicorp, an injectable combination drug treatment for erectile
dysfunction, for which Ardana has marketing and manufacturing rights in
Europe;
* Teverelix LA, in development for three initial indications (prostate
cancer, BPH and endometriosis);
* Testosterone Cream, a transdermal testosterone delivery system in
development for the treatment of male hypogonadism, in Phase II trials; and
* Oral GHS (EP01572) a oral growth hormone secretagogue in late stage
development in the first indication for the diagnosis of growth hormone
deficiency and in early stage development in a second indication.
In addition, Ardana has a strong portfolio of follow-on products in development.
Ardana is listed on the Main Market of the London Stock Exchange.
For further information please see www.ardana.co.uk
*Source: IMS Retail Drug Monitor November 2005.
Statements contained within this press release may contain forward-looking
comments which involve risks and uncertainties that may cause actual results to
vary from those contained in the forward-looking statements. In some cases, you
can identify such forward-looking statements by terminology such as 'may', '
will', 'could', 'forecasts', 'expects', 'plans', 'anticipates', 'believes', '
estimates', 'predicts', 'potential', or 'continue'. Predictions and
forward-looking references in this press release are subject to the satisfactory
progress of research which is, by nature, unpredictable. Forward projections
reflect management's best estimates based on information available at the time
of issue.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVRSELFLASWSELE
Aura Renewable Acquisiti... (LSE:ARA)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Aura Renewable Acquisiti... (LSE:ARA)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024